Dermatology Education Foundation DERM NP/PA CME Conference — Alopecia Spotlight

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the DERM2025 meeting.

These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.

In this list of the top 5 posters featured at the DERM 2025 conference, a variety of recent data are spotlighted in alopecia areata, atopic dermatitis, and other disease states.

This summary covers a variety of notable DERM 2025 conference news highlights, specifically in the area of alopecia areata.

This segment of Hebert’s DERM 2025 interview highlights additional conclusions from her team’s data on roflumilast in atopic dermatitis among infants and toddlers.

These pooled THRIVE-AA1 and THRIVE-AA2 study data highlight improvements in mental health among patients with alopecia given deuruxolitinib.

During this DERM 2025 interview segment, Martinez-Dulay touches on highlights from her sessions in which she explores allergic contact dermatitis.

This session was titled ‘The Hidden Undercurrent: When Hair Loss Isn’t Alopecia Areata’ and was presented at the DERM 2025 conference by April Armstrong, MD, MPH.

Cotter highlights his DERM 2025 conference presentation on navigating the diagnosis of melanoma and gene expression profiling of skin cancer.

This interview with Hure covers 2 of her sessions at DERM 2025, including a discussion of microplastics and forever chemicals, as well as the skin’s microbiome.

This interim data was drawn from the TRACE study, highlighting real-world use of tralokinumab in adults with atopic dermatitis of the head and neck.

In this DERM2025 interview, Friedman highlighted some of the discussion points from his presentation on off-label strategies for therapeutic challenges.

In this discussion with Chilukuri, the most notable highlights from his DERM 2025 session ‘Skincare Secrets and Quick Fixes’ were covered.

In a new interview at the DERM2025 Conference, Boswell highlights a session on systemic drugs and another session on wart and molluscum imitators.

This interview with Friedman highlights the takeaways from his DERM 2025 session on managing chronic pruritus in dermatology.

This summary highlights changes in severe alopecia areata following deuruxolitinib therapy during THRIVE-AA1 and THRIVE-AA2.

This summary of the phase 3 ALLEGRO-LT study highlights several notable findings on ritlecitinib’s use among adults and adolescents with alopecia areata.